NCT04024800
Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer
Phase: Phase 2
Role: Lead Sponsor
Start: May 3, 2019
Completion: Jun 30, 2024